After-Hours Stock Movers 08/04: (ARPO) (NVAX) (LPSN) Higher; (VAPO) (NEWR) (BYND) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Twilio (TWLO) PT Raised to $255 at Rosenblatt
August 5, 2020 7:13 AM EDTRosenblatt analyst Ryan Koontz raised the price target on Twilio (NYSE: TWLO) to $255.00 (from $235.00) while maintaining a Neutral rating.
The analyst commented, "Twilio (AMC) handily beat 2Q20 revenue and earnings (+9%/+$.17 vs consensus) while the company guided 3Q20 above consensus revenue (+6%) and... More
New Relic (NEWR) PT Lowered to $77 at Needham & Company
August 5, 2020 6:58 AM EDTNeedham & Company analyst Jack Andrews lowered the price target on New Relic (NYSE: NEWR) to $77.00 (from $79.00) while maintaining a Buy rating.
The analyst commented, "NEWR reported mixed 1QFY21 results as revenue and EPS beat consensus, but commentary around recent pricing/packaging changes imply increased... More
Novavax (NVAX) PT Raised to $257 at B.Riley/FBR
August 5, 2020 6:57 AM EDTB.Riley/FBR analyst Chad L. Mabry raised the price target on Novavax (NASDAQ: NVAX) to $257.00 (from $184.00) while maintaining a Buy rating.
... MoreNovavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
August 5, 2020 6:24 AM EDTNovavax, Inc. (NASDAQ: NVAX) today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID19 vaccine with and without MatrixM adjuvant in healthy adults 18-59 years of age. NVXCoV2373, the Companys recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at medRxiv.org.
NVX-CoV2373 was well-tolerated and had a reassuring safety profile.
Overall,... More
